Given that this gene is upregulated in most cancers, including LUSC, we suggest that ALYREF could contribute to the formation of immunodeficiency niches by reducing the number of tumor-infiltrating cells, thus exacerbating LUSC progression. The gene discussed is ALYREF; the disease is cancer.